475 related articles for article (PubMed ID: 29776381)
21. Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets.
Giuliani N; Mangoni M; Rizzoli V
Exp Hematol; 2009 Aug; 37(8):879-86. PubMed ID: 19446662
[TBL] [Abstract][Full Text] [Related]
22. In vitro efficacy of cinnarizine against lymphoma and multiple myeloma.
Schmeel LC; Schmeel FC; Kim Y; Blaum-Feder S; Endo T; Schmidt-Wolf IG
Anticancer Res; 2015 Feb; 35(2):835-41. PubMed ID: 25667464
[TBL] [Abstract][Full Text] [Related]
23. New approaches to targeting the bone marrow microenvironment in multiple myeloma.
Gooding S; Edwards CM
Curr Opin Pharmacol; 2016 Jun; 28():43-9. PubMed ID: 27018230
[TBL] [Abstract][Full Text] [Related]
24. Wnt pathway in osteosarcoma, from oncogenic to therapeutic.
Cai Y; Cai T; Chen Y
J Cell Biochem; 2014 Apr; 115(4):625-31. PubMed ID: 24190862
[TBL] [Abstract][Full Text] [Related]
25. Pathogenesis and Treatment of Myeloma-Related Bone Disease.
Gau YC; Yeh TJ; Hsu CM; Hsiao SY; Hsiao HH
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328533
[TBL] [Abstract][Full Text] [Related]
26. Noncoding RNAs in the crosstalk between multiple myeloma cells and bone marrow microenvironment.
Tang W; Xu J; Xu C
Cancer Lett; 2023 Mar; 556():216081. PubMed ID: 36739065
[TBL] [Abstract][Full Text] [Related]
27. Emerging strategies for targeting cell adhesion in multiple myeloma.
Nair RR; Gebhard AW; Emmons MF; Hazlehurst LA
Adv Pharmacol; 2012; 65():143-89. PubMed ID: 22959026
[TBL] [Abstract][Full Text] [Related]
28. Resveratrol inhibits proliferation, migration and invasion of multiple myeloma cells via NEAT1-mediated Wnt/β-catenin signaling pathway.
Geng W; Guo X; Zhang L; Ma Y; Wang L; Liu Z; Ji H; Xiong Y
Biomed Pharmacother; 2018 Nov; 107():484-494. PubMed ID: 30107344
[TBL] [Abstract][Full Text] [Related]
29. Multiple myeloma: the bone marrow microenvironment and its relation to treatment.
Andrews SW; Kabrah S; May JE; Donaldson C; Morse HR
Br J Biomed Sci; 2013; 70(3):110-20. PubMed ID: 24273897
[TBL] [Abstract][Full Text] [Related]
30. New potential targets for treating myeloma bone disease.
Roodman GD
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6270s-6273s. PubMed ID: 17062712
[TBL] [Abstract][Full Text] [Related]
31. Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments.
Hu J; Hu WX
Cancer Lett; 2018 Feb; 414():214-221. PubMed ID: 29174802
[TBL] [Abstract][Full Text] [Related]
32. Aberrantly expressed LGR4 empowers Wnt signaling in multiple myeloma by hijacking osteoblast-derived R-spondins.
van Andel H; Ren Z; Koopmans I; Joosten SP; Kocemba KA; de Lau W; Kersten MJ; de Bruin AM; Guikema JE; Clevers H; Spaargaren M; Pals ST
Proc Natl Acad Sci U S A; 2017 Jan; 114(2):376-381. PubMed ID: 28028233
[TBL] [Abstract][Full Text] [Related]
33. Biology and treatment of myeloma related bone disease.
Terpos E; Christoulas D; Gavriatopoulou M
Metabolism; 2018 Mar; 80():80-90. PubMed ID: 29175022
[TBL] [Abstract][Full Text] [Related]
34. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
Shay G; Hazlehurst L; Lynch CC
J Mol Med (Berl); 2016 Jan; 94(1):21-35. PubMed ID: 26423531
[TBL] [Abstract][Full Text] [Related]
35. Targeting Multiple Myeloma Cancer Stem Cells with Natural Products - Lessons from Other Hematological Malignancies.
Issa ME; Cretton S; Cuendet M
Planta Med; 2017 Jun; 83(9):752-760. PubMed ID: 28472843
[TBL] [Abstract][Full Text] [Related]
36. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
Gan ZY; Fitter S; Vandyke K; To LB; Zannettino AC; Martin SK
Eur J Haematol; 2015 Apr; 94(4):343-54. PubMed ID: 25179233
[TBL] [Abstract][Full Text] [Related]
37. Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes.
Colombo M; Mirandola L; Platonova N; Apicella L; Basile A; Figueroa AJ; Cobos E; Chiriva-Internati M; Chiaramonte R
Leukemia; 2013 Apr; 27(5):1009-18. PubMed ID: 23307030
[TBL] [Abstract][Full Text] [Related]
38. [Bone disease in multiple myeloma and its mechanism].
Abe M
Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
[TBL] [Abstract][Full Text] [Related]
39. Pathogenesis and management of myeloma bone disease.
Christoulas D; Terpos E; Dimopoulos MA
Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944
[TBL] [Abstract][Full Text] [Related]
40. Role of osteoblast suppression in multiple myeloma.
Stewart JP; Shaughnessy JD
J Cell Biochem; 2006 May; 98(1):1-13. PubMed ID: 16440324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
